Sign Up
Stories
4D Molecular Therapeutics Raises $300 Million
Share
4DMT Presents Positive Interim Data
ARMGO Pharma's Positive Trial Results
Abeona Therapeutics Grants Inducement Aw...
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Aldeyra Therapeutics R&D Day 2024
Overview
API
4D Molecular Therapeutics, Inc. has successfully priced an upsized underwritten public offering of common stock and pre-funded warrants to raise approximately $300 million. The company's proprietary invention platform, Therapeutic Vector Evolution, leverages AAV capsid-derived sequences for customized and evolved vectors, targeting rare and large market diseases in ophthalmology, pulmonology, cardiology, and CNS through a gene editing partnership.
Ask a question
How does the gene editing partnership with 4D Molecular Therapeutics contribute to the advancement of gene therapy in addressing diverse diseases?
How might the successful funding raise impact the development and commercialization of 4D Molecular Therapeutics' gene therapy products?
What are the potential implications of leveraging synthetic AAV capsid-derived sequences for gene therapy?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage